<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5319">
  <stage>Registered</stage>
  <submitdate>20/06/2006</submitdate>
  <approvaldate>20/06/2006</approvaldate>
  <nctid>NCT00342316</nctid>
  <trial_identification>
    <studytitle>Reduced Intensity Conditioning Transplantation Versus Standard of Care in Acute Myeloid Leukemia</studytitle>
    <scientifictitle>Prospective Controlled Clinical Study of Allogeneic Stem Cell Transplantation With Reduced Conditioning (RICT) Versus Best Standard of Care in Acute Myeloid Leukemia (AML)in First Complete Remission (CR)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TRALG1/02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Myeloid Leukemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: surgery - Reduced Intensity Conditioning Stem Cell Transplantation

Experimental: Stem cell transplant (RICT) - Receiving intervention consisting of Reduced Intensity Conditioning Stem Cell Transplantation

No Intervention: Control arm - Treatment according to standard of care, i.e. not undergoing RICT


Treatment: surgery: Reduced Intensity Conditioning Stem Cell Transplantation
One of the following conditioning regimens:
Busulphan (orally or IV), fludarabine
Fludarabine, carmustine, melfalan
Cyclophosphamide, fludarabine

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall survival at 3 years after inclusion</outcome>
      <timepoint>From inclusion until death from any cause or after 36 months, whichever comes first</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to relapse from inclusion up to 3 years</outcome>
      <timepoint>Time between inclusion and date of relapse or after 36 months, whichever comes first.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life at baseline, 12 and 24 months post inclusion</outcome>
      <timepoint>From inclusion (baseline) until relapse or death from any cause or at 12 and 24 months, whichever comes first.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In RICT patients only: Safety and feasibility of the procedure from inclusion to 3 years</outcome>
      <timepoint>Non-relapse mortality (NRM) and overall survival at two occasions up to 36 months after inclusion.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In RICT patients: Incidence &amp; severity of acute and chronic GvHD from transplantation to three years after inclusion</outcome>
      <timepoint>From transplantation until end of study, up to 36 months after inclusion.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>In RICT patients: Rate of complete or partial chimerism from transplant to 3 months</outcome>
      <timepoint>At Day +100 post Tx</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Newly diagnosed patients with de novo or secondary AML

          -  Intermediate or poor risk

          -  In first complete remission

          -  Age 51-70 years

          -  Fit for the procedure

          -  Fit for further consolidation chemotherapy</inclusivecriteria>
    <inclusiveminage>51</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Planned for a full-dose allogeneic transplant</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>360</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Austalasian Leukaemia &amp;Lymphoma Group Limited - East Melbourne</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Manitoba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Saskatchewan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Estonia</country>
      <state>Tartu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Freiburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Patras</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Goteborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Luleå</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lund</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Örebro</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Vastra Gotaland Region</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>The Canadian Blood and Marrow Transplant Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australasian Leukaemia and Lymphoma Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study compares overall survival between patients with acute myeloid leukemia, who are in
      complete remission following initial treatment with chemotherapy and whose remission is
      maintained either with a transplantation of stem cells obtained from a sibling or unrelated
      donor or with standard treatment, which is additional chemotherapy.

      The study hypothesis is that the group transplanted with stem cells from a donor will have a
      superior survival compared with patients treated with standard of care.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00342316</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mats Brune, MD, PhD</name>
      <address>Göteborg University</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>